Drug name
Last update: Nov 2026Developer(s)
Dapivirine (DPV) subdermal implant
Dapivirine subdermal implant
Small molecule
NNRTI (Non-Nucleoside Reverse Transcriptase Inhibitor)
Preclinical / IND
DPV implant is a silicone-based subdermal implant designed to provide sustained systemic delivery of DPV over extended periods. DPV prevents HIV replication by inhibiting reverse transcriptase. Unlike the approved vaginal ring, the implant delivers the drug systemically, requiring distribution to genital tissues to achieve protective concentrations. The implant exhibits near zero-order release kinetics, providing consistent drug exposure with minimal fluctuation. Initial reservoir implants released approximately 5-20 µg/day for more than 246-330 days, with modelling suggesting potential multi-year activity. Formulation optimisation significantly increased release rates. Liquid-core and dip-coated reservoir designs achieved 19.5-41 µg/day, while matrix implants reached up to 185 µg/day. Enhanced release was driven by reduced membrane thickness and improved DPV solubility within the formulation. Key strengths include ultra-long-acting delivery, tunable release profiles, established silicone implant technology, and the potential to improve adherence compared with daily oral PrEP.
Under preclinical investigation
Under preclinical investigation
Transdermal
Polymeric implant
Dose: 72-91 mg dapivirine per implant
91 mg per implant
No clinical dosing regimen has been established yet
Not provided
Not provided
Queen's University Belfast (QUB) is a historic public research institution located in the heart of Belfast, Northern Ireland. Founded in 1845, it is a member of the elite Russell Group of research-intensive universities and was recently named the UK University of the Year 2026 by the Good University Guide. The university is globally celebrated for its architectural beauty, most
Not provided
Not provided
Dapivirine implants were manufactured by dispersing DPV in silicone elastomer, filling medical-grade silicone tubing to form a drug reservoir, curing the formulation, and sealing the implant ends. Optimised designs incorporated Kolliphor® EL liquid cores or dip-coated silicone membranes to enhance release. Quality testing included dimensional analysis, drug loading verification, DSC characterisation, and long-term in vitro release studies. Materials needed: 1) Micronised DPV 2) Translucent platinum-cured silicone elastomer tubing 3) Polyvinyl chloride tubing 4) Kolliphor® EL 5) Tween® 80
Waters Alliance e2695 High-performance liquid chromatography (HPLC) system coupled with a 2489 UV/Visible detector
Not provided
Kolliphor EL (Cremophor EL)
Not provided
Not provided
No human safety, tolerability, TEAE, SAE, or injection-site reaction data were reported yet
No direct efficacy data were reported, but the release rate studies show that the implant achieved sustained, near zero-order dapivirine release for 246-330 days, with optimised designs delivering up to 185 μg/day.
Clinical safety and efficacy of DPV subdermal implant remain unconfirmed and require evaluation in preclinical and human studies.
There are either no relevant patents or these were not yet submitted to LAPaL